UTMD Utah Medical Products (UTMD) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000706698
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Utah Medical Products insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for UTAH MEDICAL PRODUCTS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 18, 2022.
- The trade is 3.3% of the 21,461 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director RICHINS PAUL O sold about $65.4K of UTMD on May 18, 2023, the largest insider sale at the company since 2022.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Nov 17, 2022.
- The trade is 2.0% of the 22,311 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director RICHINS PAUL O sold about $40.8K of UTMD on Nov 18, 2022.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 11, 2022.
- The trade is 0.7% of the 22,760 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director RICHINS PAUL O sold about $14.5K of UTMD on Nov 17, 2022.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.2% of the 22,921 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director RICHINS PAUL O sold about $3.7K of UTMD on Nov 11, 2022.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Nov 18, 2021.
- The trade is 37.5% of the 5,338 shares held after it.
- No other insider sold within 30 days.
Insider activity: Director PAYNE BARBARA A sold about $170.4K of UTMD on May 11, 2022.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-5.8% year over year
below 83% of Medical Devices
Margin
29.3% net margin
more than 97% of Medical Devices
Buybacks
$206.0K repurchased, FY to 2026-06-30
below 95% of Medical Devices
Short interest
5.5% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 62% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch UTMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+22.7%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns UTMD: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in UTMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
UTMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
UTMD financials
Revenue growth
-5.8%
XBRL, annual
Net margin
29.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM UTMD
| FY Dec 2025 | $38.5M |
| FY Dec 2024 | $40.9M |
| FY Dec 2023 | $50.2M |
| FY Dec 2022 | $52.3M |
| FY Dec 2021 | $49.1M |
| Jun 2026 | $8.5M |
| Mar 2026 | $8.7M |
| Dec 2025 | $9.0M |
| Sep 2025 | $9.8M |
| Jun 2025 | $10.0M |
| Mar 2025 | $9.7M |
| Dec 2024 | $9.2M |
| Sep 2024 | $10.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+29.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM UTMD
| FY Dec 2025 | +29.3% |
| FY Dec 2024 | +33.9% |
| FY Dec 2023 | +33.1% |
| FY Dec 2022 | +31.5% |
| FY Dec 2021 | +30.1% |
| Jun 2026 | +31.5% |
| Mar 2026 | +29.9% |
| Dec 2025 | +28.4% |
| Sep 2025 | +26.8% |
| Jun 2025 | +30.6% |
| Mar 2025 | +31.3% |
| Dec 2024 | +31.7% |
| Sep 2024 | +35.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$11.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM UTMD
| FY Dec 2025 | $14.3M |
| FY Dec 2024 | $14.6M |
| FY Dec 2023 | $21.6M |
| FY Dec 2022 | $20.3M |
| FY Dec 2021 | $20.7M |
| Jun 2026 | $1.2M |
| Mar 2026 | $3.0M |
| Dec 2025 | $3.4M |
| Sep 2025 | $3.9M |
| Jun 2025 | $2.8M |
| Mar 2025 | $4.3M |
| Dec 2024 | $2.9M |
| Sep 2024 | $3.8M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity UTMD
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
60.75x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt UTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 60.75x |
| Mar 2026 | 63.51x |
| Dec 2025 | n/a |
| Sep 2025 | 58.72x |
| Jun 2025 | n/a |
| Mar 2025 | 52.12x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+8.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity UTMD
| FY Dec 2025 | +9.5% |
| FY Dec 2024 | +11.3% |
| FY Dec 2023 | +13.7% |
| FY Dec 2022 | +14.9% |
| FY Dec 2021 | +14.1% |
| Jun 2026 | +8.8% |
| Mar 2026 | +9.1% |
| Dec 2025 | +9.5% |
| Sep 2025 | +9.6% |
| Jun 2025 | +10.4% |
| Mar 2025 | +10.6% |
| Dec 2024 | +11.3% |
| Sep 2024 | +12.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets UTMD
| FY Dec 2025 | +9.2% |
| FY Dec 2024 | +10.8% |
| FY Dec 2023 | +12.8% |
| FY Dec 2022 | +13.8% |
| FY Dec 2021 | +13.0% |
| Jun 2026 | +8.5% |
| Mar 2026 | +8.8% |
| Dec 2025 | +9.2% |
| Sep 2025 | +9.2% |
| Jun 2025 | +10.0% |
| Mar 2025 | +10.0% |
| Dec 2024 | +10.8% |
| Sep 2024 | +11.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+23.8%
operating income after a 18.6% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital UTMD
| FY Dec 2025 | +26.8% |
| FY Dec 2024 | +32.1% |
| FY Dec 2023 | +37.2% |
| FY Dec 2022 | +37.0% |
| FY Dec 2021 | +30.1% |
| Jun 2026 | +23.8% |
| Mar 2026 | +26.0% |
| Dec 2025 | +26.8% |
| Sep 2025 | +26.9% |
| Jun 2025 | +29.2% |
| Mar 2025 | +30.8% |
| Dec 2024 | +32.1% |
| Sep 2024 | +34.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed UTMD
| FY Dec 2025 | +9.6% |
| FY Dec 2024 | +10.9% |
| FY Dec 2023 | +13.5% |
| FY Dec 2022 | +17.2% |
| FY Dec 2021 | +17.2% |
| Jun 2026 | +8.5% |
| Mar 2026 | +9.0% |
| Dec 2025 | +9.6% |
| Sep 2025 | +9.7% |
| Jun 2025 | +10.3% |
| Mar 2025 | +10.4% |
| Dec 2024 | +10.9% |
| Sep 2024 | +11.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
22.27x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing UTMD
| FY Dec 2025 | 16.08x |
| FY Dec 2024 | 15.52x |
| FY Dec 2023 | 18.43x |
| FY Dec 2022 | 22.29x |
| FY Dec 2021 | 24.69x |
| Jun 2026 | 21.03x |
| Mar 2026 | 18.34x |
| Dec 2025 | 16.08x |
| Sep 2025 | 17.79x |
| Jun 2025 | 15.18x |
| Mar 2025 | 14.79x |
| Dec 2024 | 15.52x |
| Sep 2024 | 15.63x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$145.3M
market value at close 2026-10-27 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value UTMD
| FY Dec 2025 | $93.5M |
| FY Dec 2024 | $125.5M |
| FY Dec 2023 | $212.8M |
| FY Dec 2022 | $289.6M |
| FY Dec 2021 | $304.1M |
| Jun 2026 | $132.3M |
| Mar 2026 | $110.2M |
| Dec 2025 | $93.5M |
| Sep 2025 | $117.8M |
| Jun 2025 | $102.7M |
| Mar 2025 | $100.9M |
| Dec 2024 | $125.5M |
| Sep 2024 | $144.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield UTMD
| FY Dec 2025 | +8.0% |
| FY Dec 2024 | +7.0% |
| FY Dec 2023 | +7.1% |
| FY Dec 2022 | +5.6% |
| FY Dec 2021 | +5.7% |
| Jun 2026 | +5.2% |
| Mar 2026 | +6.6% |
| Dec 2025 | +8.0% |
| Sep 2025 | +6.9% |
| Jun 2025 | +7.5% |
| Mar 2025 | +7.4% |
| Dec 2024 | +7.0% |
| Sep 2024 | +7.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -13%, PEG needs growth
PEG, trailing UTMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 13.85x |
| FY Dec 2022 | 1.96x |
| FY Dec 2021 | 0.65x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M |
| EPS (diluted) | 3.48 | 3.96 | 4.57 | 4.52 |
| Operating cash flow | $14.7M | $14.8M | $22.3M | $21.1M |
| Cash | $85.8M | $83.0M | $92.9M | $75.1M |
| Long-term debt | $0 | $0 | $0 | $0 |
| Buybacks | $8.4M | $20.0M | $0 | $2.5M |
| Dividends paid | $4.0M | $4.3M | $4.3M | $3.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
UTMD Stock Sonar score 4/7 axes
Find similar shapesCompareUTMD ranks highest on financial health (95th percentile) and profitability (82nd), and lowest on growth (17th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
